Top Performing Drug – Dupixent (April Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…

BySenior EditorApril 26, 2023

INSIGHTS+

Top Performing Drug of 2021 – Darzalex (March Edition)

Shots: The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs The report summarizes the key features of Darzalex including revenue…

BySenior EditorMarch 21, 2023

INSIGHTS+

Top Performing Drug of 2021 – Trulicity (February Edition)

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen Mechanism of Action: GLP-1 receptor agonist First Approval: US (Sep 18, 2014), EU (Nov 25, 2014) Revenue Analysis1 Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…

BySenior EditorFebruary 22, 2023

VIEWPOINTS

Whitney Stewart, Director of Clinical Project Management at Curebase Shares Insights from the Release of a Publication with Digital Therapeutics Alliance

Shots: Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why the DTx devices do not fit in the standards for medical devices by quoting some examples …

BySenior EditorFebruary 14, 2023

VIEWPOINTS

Toni R. Hofhine, President of ATCOR Medical (CardieX) Shares Insights from Pulse- a New at-home Heart Health Monitor

Shots: Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…

BySenior EditorFebruary 6, 2023

INSIGHTS+

Top Performing Drug of 2021 – Imbruvica (January Edition)

Active Ingredient: Ibrutinib Dosage Forms & Strengths: Capsules: 70 mg and 140 mg Tablets: 140 mg, 280 mg, 420 mg, and 560 mg Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi) First Approval: US (13 Nov 2013), EU (Oct 2014)  Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…

BySenior EditorJanuary 25, 2023

INSIGHTS+

Top Performing Drug of 2021 – Opdivo (December Edition)

Active Ingredient: Nivolumab Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial Dosage Form: Injection Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1) First Approval: US (22 Dec 2014), EU (19 Jun 2015)  Revenue Analysis of Opdivo BMS’ Opdivo gives tough competition to other drugs in the…

BySenior EditorDecember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Xarelto (November Edition)

Active Ingredient: rivaroxaban Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg Dosage Form: Tablets Mechanism of Action: Factor Xa inhibitors First Approval: US (1 Jul 2011), EU (30 Sep 2008) Revenue Analysis of Xarelto1 Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…

BySenior EditorNovember 24, 2022

THOUGHTSPOT

Neurological Clinical Trial Trends Under Pandemic and Changing Geopolitics

It has been quite evident that the trends in the number of clinical trials associated with neurological conditions have experienced many alterations over the past 8 years (2015-2022). Through our analysis, we came across, that the number of studies increased at a moderate rate between 2015-2019 until it suffered a significant dip in 2020 due…

BySenior EditorNovember 8, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

Top Performing Drug – Dupixent (April Edition)

Top Performing Drug of 2021 – Darzalex (March Edition)

Top Performing Drug of 2021 – Trulicity (February Edition)

Whitney Stewart, Director of Clinical Project Management at Curebase Shares Insights from the Release of a Publication with Digital Therapeutics Alliance

Toni R. Hofhine, President of ATCOR Medical (CardieX) Shares Insights from Pulse- a New at-home Heart Health Monitor

Top Performing Drug of 2021 – Imbruvica (January Edition)

Top Performing Drug of 2021 – Opdivo (December Edition)

Top Performing Drug of 2021 – Xarelto (November Edition)

Neurological Clinical Trial Trends Under Pandemic and Changing Geopolitics

Contact US

FOLLOW US